首页 › 基金 › E. Ohman J:or Asset Management AB › CYTK
E. Ohman J:or Asset Management AB 对 CYTK 的持仓历史
CYTOKINETICS INC · 医疗保健
E. Ohman J:or Asset Management AB 在 Q3 2026 的 13F 申报中披露持有 CYTK(CYTOKINETICS INC)305,255 股,市值约 US$20.1M,约占其申报组合的 0.45%,在其申报持仓中市值排名第 47 位。 E. Ohman J:or Asset Management AB 最近 7 个申报季度中有 7 个季度披露了 CYTK 持仓,最早可追溯至 Q1 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
E. Ohman J:or Asset Management AB 对 CYTK 的持仓演变
E. Ohman J:or Asset Management AB 于 Q1 2025 首次披露 CYTK 持仓:329,231 股(约 US$13.2M)。 该持仓在 Q2 2026 达到峰值 304,611 股,市值约 US$25.9M。 在 7 次申报中,E. Ohman J:or Asset Management AB 2 次增持、2 次减持、2 次保持不变。 最近一期申报(Q3 2026)显示持股 305,255 股、市值约 US$20.1M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2025 | 329.23K | $13.23M | 新进 |
| Q2 2025 | 407.04K | $13.45M | 增持 |
| Q3 2025 | 407.04K | $22.37M | 持有 |
| Q4 2025 | 362.96K | $23.06M | 减持 |
| Q1 2026 | 300.76K | $19.82M | 减持 |
| Q2 2026 | 304.61K | $25.95M | 增持 |
| Q3 2026 | 305.25K | $20.12M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CYTK 与 13F 数据
CYTK(CYTOKINETICS INC)属于医疗保健行业。我们追踪的基金中还有 44 只申报持有 CYTK,申报仓位最大的包括:T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CYTK 的基金
- T. Rowe Price Investment Management, Inc. 18.72M 股 · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M 股 · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M 股 · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M 股 · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M 股 · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M 股 · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M 股 · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K 股 · $83.52M · Q2 2026
- GW&K Investment Management, LLC 1.02M 股 · $67.08M · Q3 2026
- Melqart Asset Management (UK) Ltd 767.52K 股 · $65.39M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K 股 · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K 股 · $59.63M · Q2 2026
更多关于 E. Ohman J:or Asset Management AB
常见问题
How long has E. Ohman J:or Asset Management AB held CYTK?
E. Ohman J:or Asset Management AB has disclosed CYTK holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is E. Ohman J:or Asset Management AB's current position in CYTK?
As of Q3 2026, E. Ohman J:or Asset Management AB holds 305.25K shares of CYTK (CYTOKINETICS INC), valued at $20.12M, representing 0.45% of its reported portfolio and ranking #47.
Has E. Ohman J:or Asset Management AB been buying or selling CYTK?
In the latest 13F filing (Q3 2026), E. Ohman J:or Asset Management AB held unchanged its position in CYTK. The position peaked in Q2 2026 at 304.61K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.